Suven Pharma Q3 Outcomes: Web revenue surges 78% to Rs 83 crore, income up 40%

Income grew 40% YoY to Rs 307.2 crore in Q3FY25 pushed by doubling of CDMO enterprise pushed by R&D and enterprise improvement efforts.
Gross margins for the quarter stood at 71.5% and adjusted EBITDA margins stood at 38.7%.
The Hyderabad-based firm stated it’s seeing sturdy demand throughout levels on the again of secular macro tailwinds.
It stated two molecules added this quarter during which one molecule superior to Part 3 and one straight added to Part III (laterals addition), rising complete lively Part 3 tasks to fifteen with 9 molecules.
It additionally stated a beforehand highlighted constructive readout on Part III molecule has now met the first endpoint for a second indication and onboarded a brand new strategic buyer – one of many prime 5 world pharma leaders for early-to-mid-phase tasks.
“We proceed to make enterprise improvement efforts and stay targeted on high-value CDMO choices and enlargement in area of interest expertise platforms in keeping with our strategic imaginative and prescient,’ stated Vivek Sharma, govt chairman.”Our investments in ADCs and oligonucleotides with quick underlying market development place us effectively for sustained mid and long-term development,” Sharma added.